key: cord-0894951-jq1sbhpv
authors: Uckun, F.; Saeed, M.; Awili, M.; Ozercan, I.; Qazi, S.; Lee, C.; Shibli, A.; Skolnick, A.; Prusmack, A.; Varon, J.; Barrera, C.; Orhan, C.; Volk, M.; Sahin, K.
title: Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19
date: 2022-02-18
journal: nan
DOI: 10.1101/2022.02.12.22270748
sha: cb83b98ac92af17fffaf45e71fd0c8f43db1262b
doc_id: 894951
cord_uid: jq1sbhpv

Background. The identification of effective strategies capable of reducing the case mortality rate of high-risk COVID-19 is an urgent and unmet medical need. We recently reported the clinical safety profile of RJX, a well-defined intravenous GMP-grade pharmaceutical formulation of anti-oxidant and anti-inflammatory vitamins as active ingredients, in a Phase 1 study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105) (Uckun et al., Front. Pharmacol. 11, 594321. 10.3389/fphar.2020.594321). Here we report data from a pilot clinical study (RPI-015) which examined the safety, tolerability, and feasibility of using RJX in combination with clinical standard of care (SOC) in hospitalized COVID-19 patients with pneumonia (ClinicalTrials.gov Identifier: NCT04708340). In addition to our early clinical proof of concept (POC) data, we also present non-clinical POC from a mouse model of CRS and ARDS that informed the design of the reported clinical study. Methods. 13 patients, who were hospitalized with COVID-19 pneumonia and abnormally elevated serum inflammatory biomarkers markers [≥]3 months prior to the identification of the first confirmed U.S case of the Omicron variant, were treated with IV RJX (daily x 7 days) plus SOC. Non-clinical POC study examined the ability of RJX plus dexamethasone (DEX) to improve the survival outcome in the lipopolysaccharide (LPS)-Galactosamine (GalN) mouse model of fatal cytokine release syndrome (CRS), sepsis and acute respiratory distress syndrome (ARDS). Findings. In the Phase 1 clinical study, none of the 13 patients developed a treatment-related DLT, SAE, or Grade 3-5 AEs. Nine (9) of the 12 evaluable patients, including 3 patients with hypoxemic respiratory failure, showed rapid clinical recovery. In the non-clinical POC study in LPS-GalN challenged mice, the combination of RJX plus DEX was more effective than RJX alone or DEX alone, reversed the CRS as well as inflammatory tissue damage in the lungs and liver, and improved the survival outcome. Taken together, these findings provide the early clinical and non-clinical POC for the development of RJX as an adjunct to the SOC in the multi-modality management of high-risk COVID-19.

COVID-19 has a high fatality rate in elderly and high-risk populations with comorbidities, such as hypertension, diabetes, obesity, immunodeficiencies and hematologic cancers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .

Several pro-inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL6), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β), contribute to the development of a potentially fatal severe systemic inflammation in high-risk COVD-19 patients, which is known as cytokine release syndrome (CRS) and is often associated with acute lung injury (ALI) leading to ARDS and potentially multi-organ dysfunction (MOD) in rapid progression [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . A ~40% likelihood of progression to severe-critical disease and ARDS within 10 days after symptom onset has been reported for high-risk COVID-19 patients [24- Here we report data from a pilot clinical study which examined the safety, tolerability, and feasibility of using RJX in combination with clinical standard of care (SOC), including low dose Dexamethasone (DEX) (or Solumedrol) in hospitalized COVID-19 patients with pneumonia (ClinicalTrials.gov Identifier: NCT04708340). All patients were enrolled ≥3 months prior to the identification of the first confirmed U.S case of the Omicron variant. In addition to our early clinical proof of concept (POC) data, we also present non-clinical POC from a mouse model of CRS and ARDS that informed the design of the reported pilot clinical study. In the clinical study, no patient developed a treatment-related DLT, SAE, or Grade 3-5 AEs. Seventy-five % of patients showed rapid clinical recovery with resolution of the hyperinflammatory response and oxygen therapy requirements. In the non-clinical POC study in LPS-GalN challenged mice, the combination of

The safety, tolerability, and feasibility of using RJX in combination with clinical standard of care for hospitalized COVID-19 patients were evaluated in an open-label pilot study that was Part 1 of an ongoing double-blind, randomized, Phase 1/2 Study (ClinicalTrials.gov Identifier: NCT04708340). 13 patients who were hospitalized with COVID-19 pneumonia and abnormally elevated serum inflammatory biomarkers markers were with IV RJX (daily x 7 days) plus SOC. of 20 mL RJX mixed with 100 mL normal saline (total volume = 120 mL) intravenously plus SOC for 7 consecutive days. Some patients who no longer required inpatient care due to rapid improvement of their medical condition were discharged before day 7 and consequently received fewer than 7 treatments of RJX. SOC was provided until the patient was discharged. AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE (v5.0). An 8-point ordinal scale was used as an assessment of the clinical status at the first assessment of a given study day (Supplemental Methods).

severe or critical COVID-19, including 8 males and 5 females with a median age of 46 years (Range: 24-72 years) of whom 11 were White (Hispanic or Latino) and 2 were Asian (not Hispanic or Latino) were enrolled in one of the 2 cohorts of the clinical study within 0-11 days (Median: 4 days; Mean ± SE=4.5±1.0) days after initial COVID-19 diagnosis (Table S2 ). All 13 patients had imaging evidence of viral pneumonia and they were hypoxic requiring oxygen therapy. All patients were symptomatic with cough and shortness of breath. Nine patients had a fever as well. 19 with Chest X-ray/CT-documented pneumonia associated with hypoxemia and respiratory distress, elevated baseline levels of inflammation markers in blood, such as abnormally high levels of CRP, IL-6, Ferritin, and/or LDH, and had a baseline score of 4 based on the 8-point ordinal scale (Table S2) . By comparison, all 7 patients treated in Cohort 2 had critical COVID-19 with Chest X-ray/CT-documented pneumonia associated with hypoxemic respiratory failure requiring high flow oxygen therapy and/or non-invasive positive pressure ventilation (NIPPV), increased inflammation markers and had a baseline score of 3 based on the 8-point ordinal scale (Table S2) . One Cohort 2 patient withdrew consent on day 4 and was replaced with a new patient to have a total of 6 patients evaluable for response.

The study was performed according to the guidelines of the International Conference on 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and survMisc_0.5.5 in R environment. The kinetics of the CRS-related serum biomarkers were investigated using first-order exponential "decay" functions of percentage of each biomarker. The combined results for each biomarker were graphed on semi-log axis (log10 (% inhibition) = slope

x Time + Intercept). The time to 50% reduction of the serum concentration of each biomarker was calculated from the intercept and the slope of the decay function ((log10 (50) -Intercept)/slope). These operations were carried out in the R programming environment: plyr_1.8.6 and ggplot2_3.3.5.

The therapeutic activities of RJX, DEX, and RJX plus DEX were compared side by side in the LPS-GalN model of fatal CRS, sepsis and ARDS using male BALB/c mice, as previously described [26] . The RJX doses were 0.7 mL/kg (~14 µL/20 g mouse) and 1.4 mL/kg (~28 µL/20 g/mouse), and they were administered as intraperitoneal bolus injections. The doses of the active ingredients at the 0.7 mL/kg dose were 31.5 mg/kg Vitamin C, 2. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.12.22270748 doi: medRxiv preprint ml/kg of RJX, which is 15% of its MTD determined in the previously published randomized Phase 1 clinical trial in healthy volunteers.

The care and treatments of the animals were provided in accordance with the Guide for the Care and Use of Laboratory Animals. The study was approved by the Animal Care and Use Committee of Firat University (Number: 420629). Male BALB/c mice (6-8 weeks old and weighing on average 20 g), which were purchased from Laboratory Animal Center of Firat University, were randomly divided into different treatment groups, as previously reported [26] . Mice were housed in cages throughout the study, and the following conditions were maintained: temperature, 22 ± 2 °C; relative humidity, 55 ± 5%; and a 12-h light: dark cycle. As in previous studies, we applied the concealment of treatment allocation and blind outcome assessment to reduce the risk of bias Vehicle control mice were treated with 0.5 mL NS instead of RJX. NS was administered i.p 2 hours after LPS-GalN. Test mice received either RJX (0.7 ml/kg or 1.4 ml/kg) or DEX (0.1 mg/kg, 0.6 mg/kg or 6.0mg/kg) as a monotherapy in a side-by-side comparison. We also examined a combination of 0.7 mL/kg RJX with either 0.6 mg/kg or 6 mg/kg DEX at 2 hours post-LPS-GalN injection. Drugs were administered i.p. in a total volume of 0.5 ml. The human equivalent dose (HED) levels were determined as described [37] . Tissue levels of oxidative stress biomarkers superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px), ascorbic acid levels, and malondialdehyde (MDA) were determined to examine the effects of RJX, DEX, and RJX + DEX on the sepsis-associated oxidative stress. Levels of Interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in serum samples were measured by quantitative ELISA using the commercially available Quantikine ELISA kits, as previously reported [26] . At the time of death, blood samples were obtained for biomarker studies. In addition, lungs and liver were harvested, fixed in 10% buffered formalin, and processed for histopathologic examination. 3 μm sections were cut, deparaffinized, dehydrated, and stained with hematoxylin and eosin (H & E) and examined with light microscopy using a digital image capture camera by an experienced histopathologist who was blind to the study groups.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure S6) . A combination of low dose (0.7 ml/kg) RJX and high dose (6.0 mg/kg) DEX effectively reversed the increased serum levels of the systemic inflammation markers (IL-6, TNF-α, and LDH) within 24 h, and appeared to be overall more effective than DEX alone or RJX alone ( Figure S7 ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.12.22270748 doi: medRxiv preprint LPS-GalN caused severe inflammation and oxidative stress in the lungs and liver with enhanced lipid peroxidation, as measured by a marked elevation of MDA levels, and decreased tissue levels of Vitamin C as well as the anti-oxidant enzymes GSH-Px that inhibits lipid peroxidation and SOD that converts superoxide anion radicals contributing to lipid peroxidation into hydrogen peroxide and oxygen. Low dose RJX alone or in combination with DEX significantly suppressed the oxidative stress, as documented by increases in Vitamin C, GSH-Px and SOD levels that were markedly reduced by LPS-GalN ( Figure S8) . The tissue healing activity of the combination therapy in the lungs and liver was also more pronounced than the tissue healing activity of RJX alone or DEX alone ( Figure S9, Figure S10 We next evaluated the efficacy of a combination regimen that employs low dose RJX (0.7 mL/kg) plus standard dose (0.6 mg/kg) DEX. Notably, delayed treatments with low dose RJX plus standard dose DEX starting at 2 h after the LPS-GalN injection reversed the lung damage, as evidenced by significantly reduced histopathological lung scores (Figure 1) . The tissue healing activity of the combination was more pronounced than the tissue healing activity of RJX alone or DEX alone ( Figure 1A) . Hence, although treatments were delayed until the onset of fulminant cytokine storm and systemic inflammation as well as very severe lung damage, a near-complete recovery of the inflammatory lung injury was achieved in the vast majority of mice within 24 hours.

Similar to its effects on the LPS-GalN induced ALI, RJX + DEX combination significantly reduced the liver injury ( Figure 1B) . While 5 of 10 mice (50 %) treated with standard dose DEX alone and 14 of 20 mice (70%) treated with low dose RJX alone had severe residual lung injury (histopathological lung score ≥3), only 2 of 20 mice (10%) of mice treated with the DEX+RJX combination had severe residual lung damage. The observed superiority of the combination regimen was statistically significant (Figure 1C) . Similarly, while 5 of 10 DEX treated mice (50%) and 12 of 20 RJX treated mice (60%) had severe residual liver damage, only 1 of 20 mice (10%) treated with the DEX+RJX combination had severe residual liver damage and this difference was All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figure S15 ).

Efficacy. The outcome data for 12 evaluable patients are shown in Table 1 (6 from Cohort 1 and 6 from Cohort 2; Patient 008-1204 who withdrew his consent on day 4 is not shown in this table). Nine (9) of the 12 patients, including each of the 6 Cohort 1 patients and 3 of 6 Cohort 2 patients with hypoxemic respiratory failure, showed rapid clinical recovery with normalization of the blood oxygen levels. The overall survival curve is shown in Figure 5 ; the median survival was not reached. Swimmer plots. Figure S16 shows a waterfall plot depicting the maximum increase (improvement) or decrease (worsening) of the 8-point Ordinal Scale scores. The score change ranged from -2 to +5 (Median: +3.5; Mean ± SE: 2.4 ± 0.8). The score change for Cohort 1 patients (N=6) ranged from +3 to +4 (Median: +3.5, Mean ± SE : 3.5± 0.2). By comparison, the score change for Cohort 2 patients (N=6) ranged from -2 to +5 (Median: +1; Mean ± SE: 1.3±1.5). Each of the 6 patients in Cohort 1 had a baseline score of 4. Their oxygen supplementation requirements have resolved, and they were consequently discharged from the hospital between 3 to 7 days (median: 4.5 days) after initiation of protocol therapy. Hence, their scores showed a +3 (Score 7: Not hospitalized, limitation on activities and/or requiring home oxygen) to +4 improvement within a week (Score 8: Not hospitalized, no limitations on activities -corresponds to ECOG score of 0). Of the 6 patients with hypoxemic respiratory failure who had a baseline score of 3 and required high flow oxygen and/or NIPPV, 3 were discharged from hospital at 7,7, and 14 days respectively upon resolution of their hypoxemic respiratory failure with a +4-+5 improvement on the 8-point ordinal scale (Figure 6) . Two of the remaining 3 patients experienced progression of their COVID-19 requiring intubation on day 8 and one patient developed COVID-19 related complications, including sepsis with coagulopathy (day 10-17), pulmonary embolism (day 19), and fatal mesenteric ischemia (day 23) (Figure 6 , Table   S6 ).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Globally, COVID-19 now is a major cause of mortality [9, [37] [38] [39] [40] [41] . Patients with high-risk COVID-19 with viral sepsis are in urgent need of effective strategies that can prevent and/or reverse the systemic inflammatory process and its complications, including acute respiratory distress syndrome (ARDS) and multi-organ failure [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Here we report a pilot clinical study of . Early findings showed that DEX decreased the mortality risk from 40% to 28% in ventilated patients and 25%-20% for COVID-19 patients on oxygen therapy over 28 days [57] . COVID-19 patients with moderate or severe ARDS who were treated with DEX plus SOC had significantly more ventilator-free days over 28 days than the reference group treated with SOC alone [58] .

IL-1, IL-6, TNF-α, and TGF-β are important pro-inflammatory cytokines that contribute to the pathophysiology of the cytokine release syndrome (CRS), ARDS and multi-organ failure in critically sick adult COVID-19 patients with viral sepsis [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] as well as children and adolescents with COVID-19 who develop a multi-system inflammatory syndrome (MIS-C) [59] [60] [61] [62] (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Several monoclonal antibodies that serve as inhibitors of the receptors and/or signaling pathways activated by specific pro-inflammatory cytokines are being developed and evaluated as anti-inflammatory drug candidates for prevention of CRS-related complications of severe COVID-19, including but not limited to the IL-1 receptor antagonist Anakinra (Kineret), IL-6 receptor antagonist tocilizumab (Actemra), TNF-α inhibitor infliximab (Remicade) [14, 15, 22, 42, [49] [50] [51] [52] . A major potential advantage of RJX versus biotherapeutic agents such as monoclonal antibodies that inhibit specific cytokine pathways is its ability to inhibit multiple pathways combined with its low cost of production which should make it readily available in low-to middle-income countries and therefore its further development and assessment as a potential COVID-19 drug candidate has potential global relevance.

RJX is hoped to reduce the case mortality rate of severe COVID-19 by accelerating the resolution of the systemic and pulmonary inflammatory process. Here we showed that 9 of the 12 patients, including 3 patients with hypoxemic respiratory failure, showed rapid clinical recovery with resolution of the hyperinflammatory response and oxygen therapy requirements. This early clinical experience with RJX in 12 hospitalized patients with severe-critical COVID-19 warrants further investigation of its clinical impact potential. We hypothesize that the addition of RJX to a All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. survival data with statistical analysis (Panels B and C) of the different treatment groups. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.12.22270748 doi: medRxiv preprint Depicted is the overall survival curve of the 12 hospitalized COVID-19 patients shown in Figure 3 along with the corresponding censor plot. All patients were treated with RJX + institutional SOC.

Nine patients recovered and remained alive for ≥60 days.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.12.22270748 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 18, 2022. ; https://doi.org/10.1101/2022.02.12.22270748 doi: medRxiv preprint 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Clinical and immunological features of severe and moderate coronavirus disease 2019

Cytokine release syndrome in severe COVID-19

Excess deaths from COVID-19 and other causes

COVID-19 as the leading cause of death in the United States

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Prognostic factors associated with high-risk for fatal ARDS in COVID-19 and potential role for precision Medicines as part of COVID-19 supportive care algorithms

All-cause excess mortality and COVID-19-related mortality among US adults aged 25-44 Years

The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease

SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy

Severe Covid-19

Acute respiratory failure in COVID-19: is it "typical" ARDS? Crit Care

Pathogenesis of COVID-19-induced ARDS: implications for an ageing population

Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review

Rmt Balasubramaniam V. Hyperinflammatory Immune Response and COVID-19: A Double-Edged Sword. Front Immunol

SARS-CoV-2 and viral sepsis: observations and hypotheses

Characterizing clinical progression of COVID-19 among patients in Shenzhen, China: an observational cohort study

A simple practice guide for dose conversion between animals and human

COVID-19 as the Leading Cause of Death in the United States

World Health Organization. COVID-19 Weekly Epidemiological Update, edition 45. World Health Organization

Google Scholar

Coronavirus Pandemic (COVID-19

The World Mortality Dataset: Tracking excess mortality across countries during the COVID-19 pandemic

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Severe covid-19 pneumonia: pathogenesis and clinical management

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

Recovery Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

Dexamethasone in hospitalized patients with

Therapeutic potential, risks, and future projection during COVID-19 pandemic

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Methylprednisolone as adjunctive therapy for patients hospitalized

a randomized, double-blind, phase IIb

Hyperinflammatory shock in children during COVID-19 pandemic

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. received 0.5 ml of LPS-GalN (consisting of 100 ng of LPS plus 8 mg of D-galactosamine) i.p. The depicted Whisker plots represent the median and values. In (A), the lung histopathological score ("lung injury score") was graded according to a 5-point scale from 0 to 4 as follows: 0, l, 2, 3, and 4 represented no damage, mild damage, moderate damage, severe damage, and very severe damage, respectively. In (B), the liver histopathological score

#### p<0.0001 as compared to LPS/GaIN+NS group, + p<0.05 as compared to LPS/GaIN+DEX group, and $ p<0

for severe damage, lung and liver histological scores were compared by Pearson's Chi-Square or Fisher's Exact test. a Fisher's Exact Chi-Square test used

Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities ECOG Activity Level: 0 -Fully active, able to carry on all pre-disease performance without restriction; 1 -Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2 -Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours. 3 -Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4 -Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair. 5 -Dead. *007-1201: The HRF did not worsen but patient developed and died of mesenteric ischemia and cardiac arrest as Grade 5 SAEs. Patient 008-1204 who withdrew his consent on day 4 is not shown in this table but included in safety analyses shown in Table S4, Table S5, and Table S6 .